Arsenal Biosciences cuts 99 jobs as it pivots to in vivo CAR-T therapy

Arsenal Biosciences announced another round of layoffs, eliminating 99 positions, which represents the majority of its workforce after a prior 50% reduction last year.

The cuts are part of a strategic shift to concentrate R&D on in vivo CAR-T cell therapies, a different approach from its earlier programs.

After the reductions the company will retain a small core team to pursue the new strategy and explore strategic options for its existing assets, including the AB-2100 autologous cell therapy for renal cell carcinoma, for which no data have been released yet.